DHDavid R. Hardten

David R. Hardten

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David R. Hardten has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Management of the Distorted Flap

    by David R. Hardten, Adeline G. Hardten, Sophia A. Hardten

  • Open Access

    Descemet Stripping Endothelial Keratoplasty in Patients With a Custom Foldable Silicone Artificial Iris: Safety and Efficacy Outcomes

    by Tu M. Md Tran, Clemence Bonnet, Piseth Dalin Chea, Ali Masoudi, Anthony J. Aldave, David R. Hardten, Kevin M. Miller

    Purpose: To assess outcomes of Descemet stripping endothelial keratoplasty (DSEK) in eyes with custom artificial iris (CAI) implantation. Methods: This is a retrospective, interventional, consecutive, surgical case series of patients who underwent DSEK after CAI implantation between 2010 and 2021 at 2 referral centers. Primary safety measures were loss of corrected distance visual acuity (CDVA), increase in intraocular pressure (IOP), development or progression of glaucoma, and intraoperative and postoperative complications. Efficacy measures were graft survival at year 1 and improvement in cosmesis at postoperative month 3. In general, measures were compared between baseline and postoperative year 1 while any complication was reported for the full follow-up period. Results: Thirty-nine eyes of 39 patients were identified. 64.1% of eyes had acquired aniridia from trauma. The mean follow-up interval was 27.7 months (range 12.2–117.4). Median CDVA improved from logMAR 1.0 to 0.7 at year 1 (P = 0.0047). At the final follow-up, permanent loss of CDVA occurred in 25.6% of eyes, of which 90% was due to glaucoma. The most common postoperative complication was IOP elevation (66.7% of eyes). Graft survival at postoperative year 1 was 82.0% (95% confidence interval, 66.3–91.4). Secondary graft failure occurred in 28.2% of eyes at a mean duration of 39.7 months (SD 27.9 months) after DSEK. Cosmesis improved among 87.2% of eyes at postoperative month 3. Conclusions: DSEK is an effective procedure for addressing corneal edema in eyes with a CAI, but a majority develop elevated IOP and graft survival is shorter than in eyes without a CAI.


  • Handling regular and irregular astigmatism during cataract surgery

    by David R. Hardten, Adeline G. Hardten

    Purpose of review: There are several different approaches to handling regular and irregular astigmatism during cataract surgery, but still much debate on which solutions are most effective given unique patient circumstances. In this review, we examine recent literature and studies to highlight some of the most effective ways to plan preoperatively, manage regular and irregular astigmatism during cataract surgery, as well as managing postoperative complications. Recent findings: Recent developments in technology have provided increased courses of action for astigmatism management during cataract surgery. Additional options of toric IOLs with presbyopic platforms, light adjustable lenses, intraocular pinhole lenses, online technological tools and platforms, wavefront or topographic laser technology, and phototherapeutic keratectomy are all effective solutions to managing regular and irregular astigmatism. In this review, we will explore optimal approaches for unique situations. Summary: With increased technology, research, and methods, correcting regular and irregular astigmatism during cataract surgery is achievable in most patients. With in-depth preoperative planning, analysis of patient-specific factors, and a tailored approach, surgeons can obtain excellent uncorrected vision for patients.


  • Diffuse Lamellar Keratitis (DLK)

    by David R. Hardten, Richard L. Lindstrom


  • Open Access

    Study design and baseline findings from the progression of ocular findings (PROOF) natural history study of dry eye

    by Peter J. McDonnell, Stephen C. Pflugfelder, Michael E. Stern, David R. Hardten, Taryn Conway, Linda Villanueva, David A. Hollander

    The aim of this research is to initiate a 5-year natural history study of dry eye disease (DED) using objectively assessed and patient-reported outcomes, to explore the hypothesis that DED is a progressive condition that has substantive and measurable impacts not only on the ocular surface, but on quality of life and visual functioning. Our objective for this report is to examine the baseline data. A multicenter, prospective, controlled, observational study of Level 2 (mild-to-moderate) DED patients based on International Task Force Delphi Panel severity grading, and controls, documented baseline measures (including tear film biomarkers and quality of life). Tear cytokine concentrations were also measured in the tear film. Patients were using artificial tears as needed. Two hundred seventeen DED patients and 67 gender- and age-matched controls were enrolled. A majority were females and Caucasian and groups did not differ significantly in terms of gender, race, or age. Differences between DED and matched controls, at baseline, included mean scores for Ocular Surface Disease Index (31.7 vs 4.1, P < 0.0001), Schirmer test (5.7 vs 15.3 mm, P < 0.0001), corneal staining (1.4 vs 0.2, P < 0.0001), conjunctival staining (1.4 vs 0.3, P < 0.0001), and tear break-up time (5.7 vs 8.5 s, P < 0.0001). Tear cytokines levels were determined and included interferon-γ, interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, tumor necrosis factor-α, epidermal growth factor, IL-13, IL-17, IL-1α, and inducible protein-10. The mean levels of IL-8 and IL-6 were slightly higher in the DED group at baseline. Blurred vision was reported as moderate/severe/very severe at baseline in 57.6% of DED patients vs.10.5% of normal controls (P < 0.0001). DED patients reported greater reductions in work and non-work productivity, as well as greater need for visits to ophthalmologists during the prior year. In this report of the baseline findings of a 5-year natural history study of DED, a striking disease burden is observed with regard to blurred vision, productivity, and visits to eye care practitioners in mild to moderate DED patients compared to normal subjects of similar ages and genders. ClinicalTrials.gov NCT00833235 on January 30, 2009.


  • Management of the Distorted Flap

    by David R. Hardten, Adeline G. Hardten, Sophia A. Hardten


  • Perforated Femtosecond Laser-Created Flap

    by David R. Hardten, Sumitra S. Khandelwal

  • Photorefractive keratectomy in eyes with atypical topography

    by David R. Hardten, Vrushali V. Gosavi

    Laser correction of refractive errors is one of the most effective surgical procedures today. Even so, the selection of patients who will have the outcomes they expect remains a major challenge. Corneal ectasia, a frustrating problem that can occur naturally with diseases such as keratoconus, has also been reported after refractive surgery. This review addresses the issues surrounding the use of surface refractive surgery in patients who may have atypical topography, which is a risk factor for ectasia. At present, available tests for predicting future corneal stability can give false positives and false negatives. Although the technology for treating irregular corneal astigmatism has improved, results in eyes with irregular astigmatism are less predictable than in eyes with regular astigmatism, even when wavefront- and topography-driven treatments are used. An increased risk for corneal instability may be associated with laser vision correction (LVC), although instability is generally thought to be less of a risk with surface ablation or photorefractive keratectomy than with laser in situ keratomileusis. Surface LVC has shown good success in improving uncorrected distance visual acuity with a relatively low rate of complications, even in eyes with topographic irregularities.


  • Evaluation of an isotonic tear in combination with topical cyclosporine for the treatment of ocular surface disease

    by David R. Hardten, Marlane J. Brown, Sandy Pham-Vang

    Purpose: To determine whether a new category of artificial tear product, carboxymethylcellulose 0.5% with compatible solutes (CMC-solutes) (Optive, Allergan, Inc., Irvine, California) improves clinical outcomes when used adjunctively with topical cyclosporine 0.05% (Restasis, Allergan, Inc., Irvine, California) for the treatment of ocular surface disease.Methods: Nineteen patients with ocular surface disease treated with cyclosporine 0.05% for at least 3 months and who had previously used other artificial tears adjunctively were enrolled. Patients discontinued their previous artificial tear and used CMC-solutes, concomitant with topical cyclosporine 0.05%. Corneal evaluation and tear production parameters were evaluated before and during combined CMC-solutes/cyclosporine treatment. Patients also completed a questionnaire before and during treatment with combined CMC-solutes/cyclosporine. Follow-up was at 1 and 3 months.Results: Most objective measures of ocular surface health were unchanged, but a...